Hepatic steatosis after switching to integrase inhibitor-based regimens does not parallel short-term weight gain.
AIDS
; 37(14): 2259-2262, 2023 11 15.
Article
en En
| MEDLINE
| ID: mdl-37877283
ABSTRACT
We studied hepatic steatosis in people with HIV (PWH) who switched to an integrase inhibitor (INSTI)-based regimen. One hundred and fifty-four PWH were included. After 48âweeks, median (Q1-Q3) weight gain was 1.2 (-0.6 to 3.8) kg and median (Q1-Q3) controlled attenuation parameter (CAP) change was -4 (-33 to 27) dB/m. Weight gain was weakly correlated with CAP change [R2 95% confidence interval (CI)â=â0.144 (-0.014 to 0.296); Pâ=â0.074)]. Changes in hepatic steatosis after switching to INSTI-based regimens do not seem to parallel weight gain after 1 year.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Infecciones por VIH
/
Inhibidores de Integrasa VIH
/
Diagnóstico por Imagen de Elasticidad
/
Hígado Graso
Límite:
Humans
Idioma:
En
Revista:
AIDS
Asunto de la revista:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Año:
2023
Tipo del documento:
Article